Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celscia Therapeutics Inc.

Division of Humanigen Inc.

Latest From Celscia Therapeutics Inc.

KaloBios Inc.

A handful of companies control the intellectual property for and offer access to human antibody discovery and engineering capabilities. KaloBios thinks it will be one of them, having built a platform of proprietary in vitro technologies for creating and optimizing human antibodies. To fully leverage the value of its technology platform, the start-up is becoming vertically integrated, via a merger with Celscia Therapeutics, which will give it the capability to not only discover and engineer clinically relevant antibodies, but also to develop them and bring them through to the clinic quickly.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Humanigen Inc.
  • Senior Management
  • Geoffrey Yarranton, PhD, CEO
    Christopher Bebbington, PhD, VP, Research
    Suha Jhaveri, Dir., Bus. Dev.
  • Contact Info
  • Celscia Therapeutics Inc.
    Phone: (650) 871-2163
    501 Grandview Drive, Suite 200
    S. San Francisco, CA 94080